Metastasis to the breast most commonly arises from a contralateral primary breast malignancy; however, metastatic disease can also result from extramammary malignancies by hematogenous or lymphatic dissemination. This case report reviews an unusual presentation of primary ovarian carcinoma with metastasis to an intramammary lymph node. P rimary breast cancer is one of the most frequently occurring malignancies in women, but metastatic disease to the breast is relatively uncommon. Although malignancies metastatic to the breast parenchyma have no characteristic radiographic presentation, they can present as a rounded or oval mass at the fat-parenchymal interface. Enlarged nonfatty axillary lymph nodes with spiculated or illdefi ned margins have a strong association with an underlying malignancy. Th is case report reviews an unusual presentation of primary ovarian carcinoma with metastasis to an intramammary lymph node. Breast or axillary lymph node involvement from a primary ovarian carcinoma is rare, and ovarian carcinoma metastatic to the breast is associated with a poor prognosis, as it is usually related to widespread systemic disease.
CASE REPORT
An asymptomatic 58-year-old woman with no signifi cant past medical or family history presented for a routine screening mammogram, which revealed a 1.0 cm mass in the upper outer quadrant of the left breast, favored to refl ect an enlarging intramammary lymph node (Figure 1a ). An additional enlarged lymph node was noted in the right axilla. Further evaluation with bilateral breast ultrasound confi rmed a mass in the upper outer quadrant of the left breast, again favored to represent an enlarged intramammary lymph node (Figure 1b) , as well as at least two enlarged right axillary lymph nodes. An ultrasound-guided core biopsy of the left intramammary lymph node as well as an additional core biopsy of a right axillary lymph node were performed. Immunohistochemical stains were positive for paired-box gene 8 (PAX8) and Wilm's tumor gene (WT1), with a fi nal pathologic diagnosis of high-grade serous ovarian carcinoma.
Given the unexpected diagnosis of metastatic ovarian carcinoma, further evaluation and staging workup were initiated with 18 F-fl uoro-2-deoxy-D-glucose positron emission tomog- raphy/computed tomography ( 18 F-FDG PET-CT). Th e PET-CT confi rmed a hypermetabolic mass in the left hemipelvis in close association with the left ovary (Figure 2 ), corresponding to the pathologic diagnosis of ovarian carcinoma. Multifocal FDG-avid hepatic metastases were also identifi ed, as well as extensive serosal, peritoneal, mesenteric, and omental carcinomatosis (Figure 2b ). Intra-abdominal FDG-avid lymphadenopathy, to include portocaval and bilateral common iliac chain lymph nodes, as well as bilateral inguinal lymphadenopathy, was demonstrated and was compatible with additional nodal metastatic disease. PET-CT evaluation of the thorax demonstrated a hypermetabolic mass in the upper outer quadrant of the left breast, corresponding to the biopsy-proven malignancy (Figure  2d ), as well as hypermetabolic right axillary lymphadenopathy. Th e patient's laboratory values revealed an elevated CA-125 of 900 units/mL. Th ese collective fi ndings were compatible with stage IV metastatic ovarian carcinoma. Th e patient is currently receiving carboplatin and paclitaxel chemotherapy.
DISCUSSION
While primary breast cancer is one of the most common malignancies in women, metastatic disease to the breast is relatively rare, accounting for approximately 0.5% to 2.0% of all breast cancer cases (1) . Metastatic disease to the breast most often arises from a contralateral primary breast malignancy; however, hematogenous or lymphatic metastasis from extramammary malignancies may also occur. Th e most common extramammary malignancies known to metastasize to the breast include lymphoma, melanoma, lung, and gynecological primary cancers (1) . Studies reveal that axillary nodal metastases also most commonly occur from primary breast cancer, followed by lymphoma, and infrequently from a nonbreast primary site or an unknown primary site (2) .
Ovarian carcinoma usually presents with intraperitoneal metastases by direct seeding into the peritoneal cavity, and distant metastasis most commonly involves the lung or pleura (3).
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Mammographically, metastatic tumors to the breast parenchyma classically present as a rounded or oval noncalcifi ed mass found in the subcutaneous breast tissue at the fat-parenchymal interface. Th ey generally lack the features of primary breast malignancy such as microcalcifi cations, spiculation, or architectural distortion. Intramammary or axillary lymph node enlargement can also occur, and ill-defi ned or spiculated nodal margins show a signifi cant association with malignancy (2). Specifi cally, ovarian cancer metastatic to the breast parenchyma can present as a focal mass without defi nite characteristic radiographic features (6); however, a few studies reveal that serous ovarian carcinoma metastatic to axillary lymph nodes can occasionally demonstrate a peripheral amorphous lymph node calcifi cation pattern on a mammogram (7), which is related to psammoma body formation. Th is calcifi cation pattern could potentially be used to diff erentiate from metastatic breast carcinoma, which typically demonstrates pleomorphic lymph node calcifi cations. Th is case also highlights the utility of PET-CT in detecting suspected metastatic disease such as ovarian carcinoma. PET-CT can be particularly useful for site-specifi c treatment planning such as biopsy, surgery, or radiotherapy (8) .
Breast and ovarian tumors can be diffi cult to pathologically distinguish due to overlapping morphology (9) , and immunohistochemistry may be required to distinguish the two. Estrogen and progesterone receptor expression are inadequate markers, as these can be seen in both breast and ovarian neoplasms. PAX8 has been shown to be an excellent distinguishing marker between ovarian and breast carcinoma, as it is positive in nearly all ovarian carcinoma stains and is negative in breast cancer stains (10, 11) . WT1 can also be a sensitive marker for serous ovarian carcinoma since it is rarely positive for breast cancer samples but is immunoreactive in up to 85% of ovarian samples (10, 11) .
Ovarian carcinoma metastatic to the breast is associated with a poor prognosis, largely because it is associated with widespread systemic dissemination of disease (3). On average, ovarian carcinoma metastatic to the breast is diagnosed 2 years following the initial diagnosis of ovarian cancer (12) . Several studies have demonstrated survival rates ranging from 13 days to 3.5 years following detection of metastatic disease in the breast (12) , and the 1-year survival rate has been reported at 40% (13) . With the unanticipated diagnosis of metastatic ovarian carcinoma, this case not only highlights the signifi cance of imaging workup at diagnosis, but also the value of multidisciplinary communication between the radiologist, pathologist, and clinician.
